Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31483575 | 0.92 | SLC6A2 (0.58) | SLC6A2OPRM1NTSR2NTSR1OPRD1 | |
| SCHEMBL30343609 | 0.90 | OPRM1 (0.56) | SLC6A2OPRM1NTSR2NTSR1OPRD1 | |
| SCHEMBL29746989 | 0.90 | SLC6A2 (0.54) | SLC6A2OPRM1NTSR2NTSR1NMUR2 | |
| SCHEMBL29579575 | 0.90 | CMA1 (0.58) | SLC6A2OPRM1OPRD1 | |
| SCHEMBL30690383 | 0.88 | OPRM1 (0.56) | SLC6A2OPRM1NTSR2NTSR1OPRD1 | |
| SCHEMBL29416554 | 0.88 | SLC6A2 (0.64) | SLC6A2OPRM1 | |
| SCHEMBL29470188 | 0.87 | OPRM1 (0.61) | SLC6A2OPRM1OPRD1 | |
| SCHEMBL29496921 | 0.87 | SLC6A2 (0.66) | SLC6A2OPRM1OPRD1 | |
| SCHEMBL31114351 | 0.87 | SLC6A2 (0.54) | SLC6A2OPRM1OPRD1 | |
| SCHEMBL30844215 | 0.87 | SLC6A2 (0.59) | SLC6A2NTSR2NTSR1NMUR2SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12449422-B2 | Method and composition matter for immunoproteasome-mediated delivery into living cells | PURDUE RESEARCH FOUNDATION (US) | 2025-10-21 | — | — | US | disclosed |
| US-20220120756-A1 | METHOD AND COMPOSITION MATTER FOR IMMUNOPROTEASOME-MEDIATED DELIVERY INTO LIVING CELLS | PURDUE RESEARCH FOUNDATION (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220120756-A1 | METHOD AND COMPOSITION MATTER FOR IMMUNOPROTEASOME-MEDIATED DELIVERY INTO LIVING CELLS | EXOSC5, PSMG3, EXOSC4 | SLC6A2 3800/4885OPRM1 4121/4885NTSR2 3816/4885 |
| US-12449422-B2 | Method and composition matter for immunoproteasome-mediated delivery into living cells | EXOSC5, PSMG3, EXOSC4 | SLC6A2 3800/4885OPRM1 4121/4885NTSR2 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.